Free Trial
NYSE:PRME

Prime Medicine 3/7/2025 Earnings Report

Prime Medicine logo
$6.32 -0.35 (-5.25%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$6.57 +0.25 (+3.96%)
As of 10/3/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Prime Medicine EPS Results

Actual EPS
-$1.65
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
-$2.18

Prime Medicine Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Prime Medicine Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Prime Medicine Earnings Headlines

Lost Decade warning – do this now
With the Magnificent 7 trading at bubble-like valuations, another “Lost Decade” could be looming — but Porter Stansberry says a handful of obscure “America’s Lost Stocks” have quietly delivered 1,100%–2,900% gains and may be the safest path forward now.tc pixel
See More Prime Medicine Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Prime Medicine? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Prime Medicine and other key companies, straight to your email.

About Prime Medicine

Prime Medicine (NYSE:PRME) (NYSE: PRME) is a clinical-stage genetic medicines company focused on harnessing the potential of prime editing, an advanced CRISPR-derived gene editing technology. By refining the tools required for precise correction of disease-causing mutations, Prime Medicine aims to develop single-dose treatments that address underlying genetic drivers of disease. The company applies its proprietary engineering and delivery platforms to optimize on-target efficiency and minimize off-target effects, positioning itself at the forefront of next-generation gene editing therapeutics.

Prime Medicine’s research and development efforts span multiple therapeutic areas, including rare genetic disorders, immuno-oncology, and autoimmune diseases. The company is advancing several preclinical and clinical candidates designed to correct mutations in genes associated with inherited diseases, as well as to modulate immune cell function for the treatment of cancer and chronic inflammatory conditions. Through strategic collaborations and internal discovery programs, Prime Medicine seeks to establish a diverse pipeline of genome-editing therapies with potential for durable clinical benefits.

Founded in 2021 as a spin-out from leading academic laboratories at the Broad Institute of MIT and Harvard, Prime Medicine is headquartered in Cambridge, Massachusetts. Since inception, the company has assembled a team of experts in molecular biology, delivery science, and translational medicine, and has secured substantial venture capital backing to propel its platform toward clinical milestones. By leveraging its scientific heritage and industry partnerships, Prime Medicine is committed to transforming the treatment landscape for patients with serious genetic and immune-mediated diseases.

View Prime Medicine Profile

More Earnings Resources from MarketBeat